Nancy Whiting

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

Ranjana H. Advani, Andres Forero‐Torres, Richard R. Furman et al. · Journal of Clinical Oncology · 2009 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

M. A. Hussein, James R. Berenson, Rubén Niesvizky et al. · Haematologica · 2010 · 141 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Nizar M. Tannir, Andres Forero‐Torres, Radhakrishnan Ramchandren et al. · Investigational New Drugs · 2014 · 129 citations

Medicine, Clinical Sciences, Oncology +14

SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

Django Sussman, Leia M. Smith, Martha E. Anderson et al. · Molecular Cancer Therapeutics · 2014 · 129 citations

Medicine, Oncology, Pharmacology +17

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Sven de Vos, Andres Forero‐Torres, Stephen M. Ansell et al. · Journal of Hematology & Oncology · 2014 · 104 citations · Full text

Medicine, Hematology, Oncology +17